Subscribe
megaflopp / Shutterstock.com
13 February 2025NewsAmericasMarisa Woutersen

Courtroom report: Regeneron’s $6bn biosimilar battle against Mylan

The company’s key Eylea treatment patents faced intense scrutiny as the US Federal Circuit heard Williams & Connolly, RMMS Legal, and McGuireWoods argue over criticality, stability, and validity.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Regeneron prevails in eye treatment dispute and immediately launches new suit
2 January 2024   District judge ruled in favour of Regeneron confirming patent infringement by Mylan | Court recognised Mylan's success in challenging the validity of certain patents | Ruling happened while Regeneron filed a separate case against another competitor alleging the infringement of 51 patents.
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024   Regeneron loses bid to block Eylea copy at US appeals court | Biotech says decision ‘not the final word’ in litigation
Americas
Regeneron holds off copies of $6bn eye treatment
4 February 2025   Federal Circuit upholds preliminary injunctions blocking highly similar versions of Eylea | Samsung Biopeis and Formycon failed to convince that the patent-in-suit was invalid.


Editor's picks

Americas
Fed Circ ruling on Wuhan import ban shakes up economic prong analysis
11 February 2025

Editor's picks

Americas
Fed Circ ruling on Wuhan import ban shakes up economic prong analysis
11 February 2025
Careers
Bristows appoints Irish patent attorney to boost UPC representation
4 February 2025
Americas
New national rankings recognise top US patent firms and lawyers
4 February 2025
Europe
UK court upholds EU SPC precedent, rejecting MSD’s appeal
30 January 2025
Americas
ADCs, TCR, and multimodal AI: Transformative trends in 2025
23 January 2025
Americas
Trump nixes Biden’s Executive Order on drug pricing
21 January 2025

More on this story

Big Pharma
Regeneron prevails in eye treatment dispute and immediately launches new suit
2 January 2024   District judge ruled in favour of Regeneron confirming patent infringement by Mylan | Court recognised Mylan's success in challenging the validity of certain patents | Ruling happened while Regeneron filed a separate case against another competitor alleging the infringement of 51 patents.
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024   Regeneron loses bid to block Eylea copy at US appeals court | Biotech says decision ‘not the final word’ in litigation
Americas
Regeneron holds off copies of $6bn eye treatment
4 February 2025   Federal Circuit upholds preliminary injunctions blocking highly similar versions of Eylea | Samsung Biopeis and Formycon failed to convince that the patent-in-suit was invalid.

More on this story

Big Pharma
Regeneron prevails in eye treatment dispute and immediately launches new suit
2 January 2024   District judge ruled in favour of Regeneron confirming patent infringement by Mylan | Court recognised Mylan's success in challenging the validity of certain patents | Ruling happened while Regeneron filed a separate case against another competitor alleging the infringement of 51 patents.
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024   Regeneron loses bid to block Eylea copy at US appeals court | Biotech says decision ‘not the final word’ in litigation
Americas
Regeneron holds off copies of $6bn eye treatment
4 February 2025   Federal Circuit upholds preliminary injunctions blocking highly similar versions of Eylea | Samsung Biopeis and Formycon failed to convince that the patent-in-suit was invalid.

More features

'A very good decision’: Patent industry welcomes UPC in-house reps update
Make a difference: Cast your vote in IP Diversity & Inclusion Awards 2025
Fed Circ ruling on Wuhan import ban shakes up economic prong analysis
Meet the new hire driving Bristows’ UPC strategy
Morgan Lewis expands team with five-partner hire
Fed Circ raises ‘gamesmanship’ fears in rare patent term dispute
Whoop faces suit over tech in health tracker watch
Regeneron holds off copies of $6bn eye treatment